Clinical Trial Update: Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura [Phase 3]

View source ↗

Summary

Phase III trial of caplacizumab in acquired thrombotic thrombocytopenic purpura has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Thrombotic Thrombocytopenic Purpura

Drugs mentioned

• Caplacizumab (caplacizumab)

Snippet

Sponsor: Ablynx, a Sanofi company | Conditions: Acquired Thrombotic Thrombocytopenic Purpura | Phase 3 | Status: COMPLETED | Results posted: 2019-05-22